Valuation: Atossa Therapeutics, Inc.

Market Cap 24.45M 21.85M 20.38M 18.51M 34.87M 2.37B 35.13M 245M 95.68M 1.2B 91.79M 89.8M 3.87B P/E 2026 *
-0.65x
P/E 2027 * -0.88x
Enterprise Value 24.45M 21.85M 20.38M 18.51M 34.87M 2.37B 35.13M 245M 95.68M 1.2B 91.79M 89.8M 3.87B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+0.20%
1 week+25.90%
Current month+25.90%
1 month-2.39%
3 months-1.41%
6 months-49.69%
Current year-72.26%
1 week 1.96
Extreme 1.96
2.54
1 month 1.82
Extreme 1.82
2.61
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
49.95
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap. Importance
12/5/26
Ensisheim Partners LLC
OtherCompany 0 0% -
12/5/26 Free

Director

10,000 0.1161%
12/5/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+25.90%-83.80%-76.28% 24.45M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.57% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
-0.29%-2.72%+328.78%+684.00% 42.84B
-0.53%-3.65%+28.97%+29.82% 42.79B
+0.29%-0.53%+6.56%+110.67% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
+0.45%-2.18%-9.33%-12.03% 24.05B
Average +0.25%+2.08%+39.51%+102.34% 39.43B
Weighted average by Cap. +0.65%-0.54%+56.09%+128.51%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.54M -29.42M -26.72M -50.33M -3.41B -50.71M -354M -138M -1.74B -133M -130M -5.58B -38.03M -33.98M -31.7M -28.79M -54.23M -3.68B -54.63M -381M -149M -1.87B -143M -140M -6.01B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
08/10/26 US$2.455 +0.20% 11,356
06/10/26 US$2.450 0.00% 54,625
05/10/26 US$2.450 +4.70% 53,315
02/10/26 US$2.340 +3.08% 74,271
01/10/26 US$2.270 +16.41% 113,600
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.450USD
Average target price
19.00USD
Spread / Average Target
+675.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock